Aromatherapy Inhaler Use for Hematopoietic Stem Cell Transplant Patient Distress
Stanford University
Summary
The purpose of this research is to evaluate aromatherapy inhaler use and how it may impact cancer distress and coping by patients in the first few days after hematopoietic stem cell transplant (HSCT).
Description
Phase 1: Transplant Day +1, +2, or +3. Phase 2: Washout Day: Standard of care (SOC) pharmacological intervention only. Phase 3: Transplant Day +3, +4, or +5). Study Completion: Transplant Day +4, +5, or +6. \*Study activities will occur on a single day for each phase. However, a three-day window for Phases 1 and 3 will allow consideration of patients' ability to participate in the immediate post-transplant period.
Eligibility
- Age range
- 19+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Autologous and Allogeneic patients admitted to E1 for planned HSCT * Patients with hematologic malignancies requiring HSCT * No allergies to lavender or peppermint essential oils * Must have received chemotherapy during preparative regimen (single or multi-agent regimen) * Adult patient over 18 years of age * Able to speak, read, and comprehend English * Willing and capable of providing informed consent Exclusion Criteria: * Patients admitted for Chimeric Antigen Receptor T cell (CART) infusion * Patients receiving a transplant for a germ cell tumor diagnosis * Unexpec…
Interventions
- OtherAromatherapy Inhaler
Lavender Aromatherapy Inhaler Peppermint Aromatherapy Inhaler
Location
- Stanford UniversityStanford, California